Override: HHS Revokes FDA’s LDT Policies
Executive Summary
The US department that oversees the FDA says the agency acted beyond its authority in asking labs to file emergency use authorizations, asserting that only CLIA rules should apply.
You may also be interested in...
US Election 2020: What Does A Trump Or Biden Win Mean For FDA Regulations?
Experts say either would likely prioritize issues such as the coronavirus pandemic and the medical supply chain, but they would diverge in areas like laboratory developed test reform.
Gottlieb vs Azar vs Califf vs Gottlieb: The Public Fight Over How The US FDA Should Operate
Yes, Gottlieb’s in there twice; things get complicated when an agency starts to lose credibility.
Spurred On By HHS Policy Shift, AdvaMed Chief Wants LDT Reform In User-Fee Negotiations
The medical device advocacy group plans to include laboratory developed test reform in their upcoming user-fee negotiations with the US FDA.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Medtech Insight?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: